Newsletter | December 16, 2024

12.16.24 -- The Fork In The Road: Personal Decisions That Change Our Career Trajectory

SPONSOR

Challenging the Norm: Smaller Partners, Bigger Impact

In our outsourcing industry, it is never an easy decision to select a partner when trying to run complex sequential trials. The need to gain regulatory approval for the treatments you have dedicated yourself to providing, coupled with the need to find a capable, reliable, and fair Contract Research Organization is quite daunting. Discover how a smaller full-service partner may be better suited to see your study through.

FEATURED ARTICLE

The Fork In The Road: Personal Decisions That Change Our Career Trajectory

Novo Nordisk SVP Blandine Lacroix shares her career story and discusses the importance of prioritizing your own personal needs, and the personal needs of others, in navigating a professional career.

INDUSTRY INSIGHTS

How To Prepare Your Life Sciences Company For A Successful IPO

When you're preparing for an IPO, it's important to consider transitioning to a scalable ERP system, enabling your life science company to efficiently handle financial data.

The Sponsor's Clinical Development Handbook For Gene Therapy Trials

Gene therapy has existed for decades, but the field is not as mature as it may seem. Find essential insights and strategies for overcoming gene therapy development challenges.

The Evolution Of The Modern Medical Monitor

Learn how to identify, hire, and empower a modern medical monitor to help your next study proceed toward submission more productively and with greater data integrity than ever before.

Intelligent Compliance: Transforming Clinical Trial Disclosure With AI

Unlock the full potential of AI by fostering collaboration across clinical, regulatory, data management, and IT teams to ensure seamless integration and alignment on AI adoption goals.

Customized Release Through Dispersed Dosage Formats

Typically, dosage format is based on the target product profile: how the developer envisions the product best addressing a clinical indication by maintaining population-wide efficacy.

Improving Therapeutic Protein Efficacy Through Charge Profile Adjustment

By adequately measuring charge variants early in development and implementing effective control strategies, developers can mitigate risks and ensure the safety and efficacy of their mAb products.